LB Pharmaceuticals Inc [LBRX] stock prices are up 6.95% to $21.07 at the moment. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The LBRX shares have gain 10.17% over the last week, with a monthly amount glided 32.72%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
LB Pharmaceuticals Inc [NASDAQ: LBRX] stock has seen the most recent analyst activity on October 06, 2025, when Stifel initiated its Buy rating and assigned the stock a price target of $27. Previously, Piper Sandler started tracking the stock with Overweight rating on October 06, 2025, and set its price target to $78. On October 06, 2025, Leerink Partners initiated with a Outperform rating and assigned a price target of $34 on the stock.
The stock price of LB Pharmaceuticals Inc [LBRX] has been fluctuating between $13.36 and $23.15 over the past year. Currently, Wall Street analysts expect the stock to reach $34.5 within the next 12 months. LB Pharmaceuticals Inc [NASDAQ: LBRX] shares were valued at $21.07 at the most recent close of the market. An investor can expect a potential return of 63.74% based on the average LBRX price forecast.
Analyzing the LBRX fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -1.88, Equity is 0.98 and Total Capital is -2.55. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at -0.04.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 20.08 points at the first support level, and at 19.08 for the second support level. However, for the 1st resistance point, the stock is sitting at 21.68, and for the 2nd resistance point, it is at 22.28.
Ratios To Look Out For
It’s worth pointing out that LB Pharmaceuticals Inc [NASDAQ:LBRX]’s Current Ratio is 47.60. In addition, the Quick Ratio stands at 47.60 and the Cash Ratio stands at 2.83.
Transactions by insiders
Recent insider trading involved Deep Track Biotechnology Maste, 10% Owner, that happened on Sep 12 ’25 when 2.0 million shares were purchased. 10% Owner, Deep Track Biotechnology Maste completed a deal on Sep 12 ’25 to buy 0.67 million shares. Meanwhile, 10% Owner Pontifax Management 4 G.P. (20 bought 1.0 million shares on Sep 12 ’25.
